Radius Health (NASDAQ:RDUS) Stock Price While Sentiment Improves

Radius Health, Inc. (NASDAQ:RDUS) Logo

Sentiment for Radius Health (NASDAQ:RDUS)

Radius Health (NASDAQ:RDUS) institutional sentiment increased to 1.72 in 2018 Q2. Its up 0.93, from 0.79 in 2018Q1. The ratio is better, as 67 hedge funds opened new or increased holdings, while 39 reduced and sold their positions in Radius Health. The hedge funds in our partner’s database now have: 51.82 million shares, down from 54.99 million shares in 2018Q1. Also, the number of hedge funds holding Radius Health in their top 10 holdings was flat from 3 to 3 for the same number . Sold All: 19 Reduced: 20 Increased: 44 New Position: 23.

Radius Health, Inc., a biopharmaceutical company, develops and sells therapeutics in the areas of osteoporosis, oncology, and endocrine diseases primarily in the United States. The company has market cap of $721.35 million. The Company’s product candidates include Abaloparatide-SC, an injectable subcutaneous formulation of abaloparatide, which has completed Phase III clinical trial for the treatment of patients with postmenopausal osteoporosis; and Abaloparatide-TD, a transdermal patch for use as a short wear-time transdermal patch. It currently has negative earnings. The firm is also involved in developing RAD1901, a selective estrogen receptor down-regulator/degrader, which is in Phase I clinical trial for the treatment of metastatic breast cancer, as well as in Phase IIb clinical trial for the treatment of postmenopausal vasomotor symptoms; and RAD140, a nonsteroidal selective androgen receptor modulator for the treatment of breast cancer.

The stock decreased 2.94% or $0.48 during the last trading session, reaching $15.84. About 746,215 shares traded. Radius Health, Inc. (NASDAQ:RDUS) has declined 47.36% since December 8, 2017 and is downtrending. It has underperformed by 62.98% the S&P500.

Analysts await Radius Health, Inc. (NASDAQ:RDUS) to report earnings on March, 7. They expect $-1.27 earnings per share, up 20.13 % or $0.32 from last year’s $-1.59 per share. After $-1.09 actual earnings per share reported by Radius Health, Inc. for the previous quarter, Wall Street now forecasts 16.51 % negative EPS growth.

Mpm Asset Management Llc holds 45.65% of its portfolio in Radius Health, Inc. for 4.00 million shares. Bb Biotech Ag owns 6.20 million shares or 5.28% of their US portfolio. Moreover, Senzar Asset Management Llc has 5.15% invested in the company for 60,521 shares. The New York-based Healthcor Management L.P. has invested 1.89% in the stock. Rock Springs Capital Management Lp, a Maryland-based fund reported 1.13 million shares.

Since January 1, 0001, it had 4 insider purchases, and 0 selling transactions for $7.31 million activity.

Radius Health, Inc. (NASDAQ:RDUS) Ratings Coverage

Ratings analysis reveals 100% of Radius Health’s analysts are positive. Out of 3 Wall Street analysts rating Radius Health, 3 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $47 while the high is $60. The stock’s average target of $52 is 228.28% above today’s ($15.84) share price. RDUS was included in 5 notes of analysts from June 11, 2018. On Wednesday, July 25 the stock rating was maintained by Bank of America with “Buy”. JP Morgan maintained Radius Health, Inc. (NASDAQ:RDUS) rating on Monday, July 23. JP Morgan has “Overweight” rating and $59 target. JP Morgan maintained it with “Overweight” rating and $60 target in Monday, June 11 report. The firm has “Overweight” rating by JP Morgan given on Friday, November 2. As per Thursday, October 11, the company rating was maintained by Morgan Stanley.

More notable recent Radius Health, Inc. (NASDAQ:RDUS) news were published by: Seekingalpha.com which released: “Radius Health’s (RDUS) CEO Jesper Høiland on Q2 2018 Results – Earnings Call Transcript – Seeking Alpha” on November 01, 2018, also Seekingalpha.com with their article: “Is Radius Health Worth Your Time? – Seeking Alpha” published on March 31, 2018, Nasdaq.com published: “Radius Health Announces Positive Data on Lead Drug Tymlos – Nasdaq” on March 19, 2018. More interesting news about Radius Health, Inc. (NASDAQ:RDUS) were released by: Globenewswire.com and their article: “Radius Health Provides Update on CHMP Opinion for Abaloparatide-SC – GlobeNewswire” published on March 22, 2018 as well as Globenewswire.com‘s news article titled: “Radius Health to Announce Third Quarter 2018 Financial Results, Host Conference Call and Live Webcast on November 1, 2018 – GlobeNewswire” with publication date: October 12, 2018.

Radius Health, Inc. (NASDAQ:RDUS) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.